Capricor Therapeutics | CAPR - Cash And Equivalent


Capricor Therapeutics reported $105.42M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Bioline Rx USD 7.91M 725K Sep/2025
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
Geron USD 68.9M 10.54M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Immunic USD 186.63M 171.15M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Plus Therapeutics USD 3.02M 1.23M Mar/2026
Prothena USD 329.46M 21.93M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026